Tumor cells with defective type I interferon signaling

Tumor cells with defective type I interferon (IFN) signaling represent a cellular phenotype characterized by an inability to mount an innate antiviral response. In healthy cells, type I interferons (IFN-alpha and IFN-beta) bind to the IFNAR receptor complex, triggering the JAK-STAT signaling pathway to produce interferon-stimulated genes (ISGs) that block viral replication and promote apoptosis (Zitvogel et al., 2015). Many cancers lose this signaling capability through mutations in JAK1, STAT1, or the loss of IFNAR1/2 to evade immune-mediated destruction (Stojdl et al., 2000). This defect creates a unique therapeutic window for oncolytic viruses, which are engineered or naturally inclined to replicate only in cells lacking these antiviral defenses. While normal cells produce IFN to halt viral spread, these defective tumor cells allow the virus to replicate unchecked, leading to selective oncolysis and the release of tumor-associated antigens. Consequently, this signaling deficiency is a major biomarker for the efficacy of viral-based therapies like Talimogene laherparepvec and VSV-IFNbeta (Xia et al., 2016). Understanding this defect is crucial for patient selection, as tumors with intact IFN signaling may be resistant to certain oncolytic platforms (Barber, 2005).

Other names

IFN-deficient tumor cellsType I IFN signaling-deficient cancer cellsInterferon-nonresponsive tumor cellsIFN-pathway-deficient tumors

Oncolytic viruses exploit the lack of interferon-mediated antiviral defenses in these cells to achieve selective replication and subsequent cell lysis (oncolysis).